This page contains a Flash digital edition of a book.

Roger Stupp is an Attending Physician in the Department of Neurosurgery at the University of Lausanne Medical Centre (CHUV) and Head of the Department of Oncology of the Riveria/Chablais region at the hospitals of Vevey and Monthey, Switzerland. His clinical interests include the multimodality management of primary and secondary brain tumours, head and neck tumours and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. Dr Stupp is Vice President of the European Organisation for Research and Treatment of Cancer (EORTC), and he is the former secretary of the Brain Tumour Group. He also serves as associate editor or member of the editorial boards for numerous journals, including the European Journal of Cancer, Journal of Clinical Oncology, Neuro-Oncology and Oncology.

elcome to the latest edition of European Oncology & Haematology. It reflects once again the great diversity of our speciality, with articles covering supportive care, acute and late toxicity of cancer care, advances in head and neck cancer and other solid tumours and challenges in imaging and diagnostic procedures exemplified in brain tumours, breast and lung cancers. New to this year’s edition is a haematological section including haematological malignancies and coagulation disorders (previously covered in a separate edition). With satisfaction I notice the merging of oncology and haematology.


Radiation therapy is a mainstay of cancer therapy. As recent progress allows more frequently for recovery or at least prolonged survival, late treatment toxicity is of increasing concern. Irradiation of frequent childhood tumours such as medulloblastoma and ependymoma is frequently associated with late neurocognitive and neuroendocrine dysfunction. To learn more, read the excellent article by Urbach, Laperriere and Bartels. They document the high incidence of endocrine dysfunction that may shorten survival and lead to substantial loss in quality of life and speculate whether novel 3D radiation techniques allow for a substantial reduction in toxicity.

Novel technologies and their integration into clinical practice is also the subject of an article on the increasing use of magnetic resonance imaging (MRI) for breast cancer. The authors advocate this very sensitive tool for planning in patients undergoing breast-conserving surgery, as it may change the planned treatment in up to 20% of patients. However, they also underline that technology alone is not sufficient and that the necessary expertise in the interpretation of breast radiology is often lacking.

The importance of expertise is also evident in the surgical treatment of pancreatic cancer and may explain in part the contradictory trial results of adjuvant therapy. Bergenfeldt and Andren-Sandberg accurately review the history and various techniques of pancreatic surgery and outline the European data supporting adjuvant chemotherapy, in contrast to US data favouring concomitant adjuvant chemoradiotherapy.

Mediastinal staging is key to risk-adapted therapy in non-small cell lung cancer. Numerous novel techniques and technologies have increased the pre-operative accuracy and positron-emission tomography (PET) can now offer a substitute to invasive mediastinoscopy. Ceron and colleagues propose a mathematical model of risk assessment and the predictive value of each test, allowing to move without undue delay to surgery for truly early stage disease.

The path to clinically available thrombopoietic drugs has been long, with many unexpected hurdles. Recently, the first thrombopoietin-receptor agonists were approved for selected forms of idiopathic thrombocytopenic purpura (ITP). The available clinical data is reviewed by Stasi and colleagues.

This edition of European Oncology & Haematology emphasises the importance and influence of technological progress on medical care. I wish that we would evaluate our technological advances more rigorously, considering their impact on our daily treatment decisions and patient outcomes. Technology alone cannot be a substitute for experience, expertise and interdisciplinary collaboration in cancer care. The authors are to be thanked for their concise reviews of the topics given. European Oncology & Haematology would also like to thank all organisations and media partners for their ongoing support and the members of the Editorial Board for their continued involvement and advice. We hope that our readers will benefit from the provision of the important information incorporated in it. I wish you an enjoyable and educative read. n



Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92